What Danaher does

Danaher Corporation is a global science and technology innovator organized into three operating platforms — Biotechnology (Cytiva), Diagnostics (Beckman Coulter Diagnostics, Cepheid, Leica Biosystems, Radiometer, Mammotome, HemoCue, and Masimo following its June 2026 acquisition), and Life Sciences (SCIEX, Pall, IDT, Abcam, Aldevron, Genedata, IDBS, Beckman Coulter Life Sciences, Leica Microsystems, Molecular Devices, Phenomenex). The company serves biopharmaceutical manufacturers, biotechnology firms, clinical laboratories, hospitals, and research institutions across more than 180 countries, with named enterprise customers including Boehringer Ingelheim, Novartis, AstraZeneca, Eisai, Chugai, and Bayer Crop Science.

Its product portfolio spans mass spectrometers and chromatography columns (SCIEX, Phenomenex), bioprocessing equipment and consumables (Cytiva, Pall), molecular diagnostics (Cepheid GeneXpert), tissue pathology (Leica Biosystems), point-of-care testing (HemoCue, Radiometer), breast biopsy systems (Mammotome), patient monitoring and pulse oximetry (Masimo), oligonucleotides and CRISPR tools (IDT), antibodies and reagents (Abcam), GMP plasmid manufacturing (Aldevron), and cloud-based biopharma R&D software (Genedata Vico, IDBS). Underlying platforms include AI-native CMC software built on Anthropic's Claude frontier models, AI-enabled OIRD pattern recognition on the Masimo smartSET platform, and proprietary ZT Scan DIA 3.0 proteomics sensitivity gains.

Danaher operates a hybrid revenue model combining capital equipment sales (instruments, bioprocessing systems) with high-recurring consumables, reagents, and service contracts tied to installed bases, supplemented by subscription revenue from BioPharma cloud software (Genedata, IDBS). Q1 2026 revenue was $5.95 billion (+3% YoY) with a 30.2% operating margin, FY2026 adjusted EPS guidance of $8.35–$8.55, $127.6B market capitalization, and ~79% institutional ownership. Operational performance is unified by the Danaher Business System (DBS), a proprietary continuous-improvement framework applied across all operating companies.

Name

Danaher

Legal name

Danaher Corporation

Website

https://danaher.com

Company type

Public

Founded year

1969

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Danaher Corporation is a global life sciences and diagnostics innovator operating across Biotechnology, Diagnostics, and Life Sciences platforms through 15+ subsidiaries, serving biopharmaceutical manufacturers, clinical laboratories, hospitals, and researchers in 180+ countries with instruments, consumables, and software.

Ownership category

akta.pro rank

Product category

Life Sciences and Diagnostics Instruments

SIC

Laboratory Analytical Instruments (3826), In Vitro & In Vivo Diagnostic Substances (2835), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Clinical Chemistry & Hematology Diagnostics (automated analyzers, blood testing) (HLAAALAH)

akta.pro secondary industries

Automation, Controls & Manufacturing Execution for Bioprocessing (SCADA/DCS/PLC/MES) (HLAAAJAE), Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D) (HLAGAJAC), mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC), Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI), Microscopy, Imaging & Flow Cytometry Instruments (HLAGAIAE)

Keywords

• Life sciences instruments
• Clinical diagnostics products
• Bioprocessing equipment
• Analytical laboratory tools
• Molecular diagnostics systems

Headquarters

HQ city

Washington

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Supply Chain, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Diagnostics Products and Services: Danaher's Diagnostics segment generates revenue through sale of clinical diagnostic instruments, reagents, and consumables. Operating companies include Beckman Coulter Diagnostics, Cepheid, HemoCue, Leica Biosystems, Mammotome, Radiometer, and Masimo (acquired 2026). Products include diagnostic instruments, patient monitoring systems, and related consumables. Revenue model combines instruments (capital equipment sales) with recurring consumables and service contracts.
2. Life Sciences Products and Services: Danaher's Life Sciences segment generates revenue through sale of analytical instruments, genomics tools, filtration systems, and laboratory equipment. Operating companies include Abcam, Aldevron, Beckman Coulter Life Sciences, Genedata, IDBS, Integrated DNA Technologies, Leica Microsystems, Molecular Devices, Pall, Phenomenex, and SCIEX. Products include mass spectrometers, PCR instruments, CRISPR tools, antibodies, and separation technologies.
3. Biotechnology Products and Services: Danaher's Biotechnology segment generates revenue through Cytiva, providing bioprocessing equipment, consumables, and services for pharmaceutical manufacturing. Products support development and commercialization of biologics, cell therapies, and gene therapies.
4. Software and Data Solutions: Operating companies like Genedata and IDBS provide cloud-based software solutions for biopharmaceutical R&D and development, generating subscription and license revenue.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Danaher designs, manufactures, and sells analytical instruments, clinical diagnostics, bioprocessing equipment, and consumables across three platforms: Life Sciences (mass spectrometry, microscopy, genomics, filtration via SCIEX, Leica, IDT, Pall, Abcam), Diagnostics (molecular diagnostics, blood gas, pathology, patient monitoring via Cepheid, Beckman Coulter, Radiometer, Leica Biosystems, Masimo), and Biotechnology (bioprocessing for biologics, cell and gene therapies via Cytiva). Revenue combines capital equipment sales with high-margin recurring consumables, reagents, software subscriptions, and service contracts to biopharmaceutical companies, clinical laboratories, hospitals, and research institutions in over 180 countries.

Product overview

Danaher operates as a global life sciences and diagnostics innovator with three operating platforms: Biotechnology, Diagnostics, and Life Sciences. The Diagnostics segment includes acquired Masimo (pulse oximetry and patient monitoring), Beckman Coulter Diagnostics, Cepheid (molecular diagnostics/GeneXpert systems), Radiometer, Leica Biosystems, Mammotome, and HemoCue. The Life Sciences platform spans SCIEX (mass spectrometry including novus V55), Integrated DNA Technologies (IDT, oligonucleotides/CRISPR), Phenomenex (chromatography columns), Genedata and IDBS (BioPharma cloud software), Pall (filtration), Beckman Coulter Life Sciences, Leica Microsystems, Molecular Devices, Abcam, and Aldevron. The Biotechnology platform centers on Cytiva for bioprocessing. Danaher completed its $9.9 billion acquisition of Masimo in June 2026, integrating it as a standalone operating company within Diagnostics. Recent product launches include the SCIEX novus V55 mass spectrometer with AI-enabled software (June 2026), Genedata Vico AI-native CMC platform (May 2026), and Masimo's FDA-cleared AI-enabled opioid-induced respiratory depression detection feature (June 2026).

Differentiator

Problem solved

Functional benefit

Products and services

• SCIEX novus V55 Mass Spectrometer System Next-generation triple quadrupole mass spectrometer for analytical laboratories with AI-enabled software for mass spectrometry data analysis, targeted at pharmaceutical, environmental, clinical research, and proteomics applications.
• Genedata Vico AI-Native CMC Platform Cloud-based AI-native platform for Chemistry, Manufacturing, and Controls (CMC) workflows in biopharmaceutical development, providing data-driven experimentation, predictive risk assessment, and real-time process monitoring for top pharmaceutical companies.
• Masimo Radius VSM with OIRD Detection FDA-cleared wearable continuous patient monitor with AI-enabled opioid-induced respiratory depression detection capability for hospital patients receiving opioid therapy, using Masimo's proprietary smartSET signal extraction pulse oximetry platform.
• Luna Omega HILIC LC Columns Hydrophilic interaction liquid chromatography columns from Phenomenex for reliable separation of polar and hydrophilic compounds across biopharmaceutical, metabolomics, clinical, environmental, and food testing applications.
• Endrix Long Life LC Columns Liquid chromatography columns from Phenomenex engineered for extended column lifetime and consistent performance in demanding analytical laboratory workflows.
• Mammotome HydroMARK Plus Breast Biopsy Site Marker CE-marked breast biopsy site marker using patented hydrogel formulation for marker stability and long-term visibility in patients undergoing breast cancer diagnosis and treatment.
• Cytiva Bioprocessing Solutions Bioprocessing equipment, single-use technologies, cell therapy platforms, and consumables for development and commercialization of biologics, cell therapies, gene therapies, and mRNA vaccines by biopharmaceutical manufacturers and CDMOs.
• Cepheid GeneXpert Molecular Diagnostic Systems Molecular diagnostic systems and cartridge-based tests for rapid infectious disease, respiratory illness, and healthcare-associated infection diagnostics at point-of-care and clinical laboratory settings.
• Beckman Coulter Diagnostics Clinical Instruments Clinical diagnostic instruments, assays, and reagents for hospital and reference laboratories supporting diagnostics across chemistry, immunoassay, hematology, and flow cytometry.
• Radiometer Blood Gas and Point-of-Care Diagnostics Blood gas analyzers and point-of-care diagnostic systems for acute care, emergency, and hospital laboratory settings.
• Leica Biosystems Digital Pathology Solutions Digital pathology instruments, staining systems, and tissue diagnostics solutions for cancer diagnostics and clinical pathology workflows.
• Pall Filtration and Purification Systems Filtration, separation, and purification technologies for life sciences research, bioprocessing, and industrial fluid applications.
• Integrated DNA Technologies (IDT) Oligonucleotide and CRISPR Products Custom oligonucleotide synthesis, CRISPR genome editing tools, and nucleic acid products for life sciences research and therapeutic manufacturing, including therapeutic oligonucleotide manufacturing (TOM) services.
• Abcam Antibodies and Reagents Antibodies, reagents, and protein research tools portfolio for life sciences research laboratories and drug discovery applications.
• IDBS Enterprise Cloud Software for BioPharma Enterprise cloud software platform for biopharmaceutical research and development data management, serving 80% of the top 20 global biopharma companies across discovery through manufacturing workflows.
• Aldevron GMP Plasmid and Nucleic Acid Manufacturing Custom plasmid DNA and GMP-grade nucleic acid manufacturing services for cell and gene therapy development and commercialization.
• Leica Microsystems Microscopy and Imaging Systems Microscopy, imaging, and optical equipment for life sciences research, clinical pathology, and industrial applications.
• Molecular Devices Bioanalytical Instrumentation Microplate readers, cellular analysis systems, and bioanalytical instrumentation for research and quality control laboratories.
• HemoCue Point-of-Care Testing Systems Point-of-care diagnostic testing systems for hemoglobin, glucose, and other diagnostic parameters in clinical and field settings.

Quantifiable outcome

• Masimo acquisition projected to be accretive to adjusted diluted EPS by $0.15-$0.20 in first full year and ~$0.70 by year five
• +3 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature6 records

Partnerships

Five partnerships are on record, tiered core.

• CellCarta and Leica BiosystemscoreStrategic or Co-development Partner · 29 May 2026CellCarta and Leica Biosystems expanded their companion diagnostic (CDx) joint development model from China to global biopharma sponsors. The collaboration introduces a flexible, end-to-end CDx development framework integrating Leica Biosystems' digital pathology capabilities with CellCarta's global laboratory network.
• Anthropic (Claude AI)coreTechnology or Integration · 19 May 2026Genedata announced partnership with Anthropic's Claude frontier model family to power its Genedata Vico AI-native CMC platform, co-developed with top 10 pharmaceutical companies.
• IDBS Customer and Partner Forum (Boehringer Ingelheim, Novartis, Eisai, Chugai, Bayer Crop Science)coreStrategic or Co-development Partner · 18 May 2026IDBS i3 2026 forum in Boston brought together scientists and digital leaders from global BioPharma community including Boehringer Ingelheim, Novartis, Eisai, Chugai, and Bayer Crop Science to showcase real-world outcomes from using IDBS cloud software.
• AWS, Elucidata, and Boehringer IngelheimcoreTechnology or Integration · 18 May 2026IDBS partnered with AWS (cloud infrastructure), Elucidata (data analytics), and Boehringer Ingelheim (end-user) to demonstrate that reliable AI execution depends on structured, contextualized data foundations and governance.
• AstraZenecacoreStrategic or Co-development Partner · 1 May 2025Danaher partnered with AstraZeneca in May 2025 to develop AI-powered precision diagnostic tools.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Thermo Fisher Scientific: Closest direct peer — a global life sciences tools, diagnostics, and laboratory instruments leader with overlapping offerings in mass spectrometry, bioprocessing (Patheon/PPC), genetic analysis, and clinical diagnostics spanning pharma, biotech, and healthcare.
• Agilent Technologies: Direct peer in analytical instruments and life sciences, with overlapping mass spectrometry, chromatography (Phenomenex competes with Agilent), and cell analysis offerings serving pharma, biotech, and academic research.
• Bio-Rad Laboratories: Direct peer in clinical diagnostics and life science research, with overlapping offerings in digital PCR, clinical chemistry (competes with Beckman Coulter), and protein separation/reagents (competes with Abcam/IDT).
• Becton, Dickinson and Company: Direct peer in life sciences instruments, flow cytometry (competing with Beckman Coulter/Molecular Devices), bioprocessing (competing with Cytiva/Pall), and clinical diagnostics — overlapping across multiple Danaher operating companies.
• Waters Corporation: Direct peer in analytical instruments, mass spectrometry (competing with SCIEX), and chromatography (competing with Phenomenex) — closely aligned with Danaher's Life Sciences instruments platform serving pharma, biotech, and academic research.
• Bruker Corporation: Direct peer in scientific instruments including mass spectrometry, microscopy (competing with SCIEX and Leica Microsystems), and proteomics — comparable analytical instruments customer base to SCIEX and Bruker Daltonics.

Broad incumbents

• Roche Holding: Broad incumbent in clinical diagnostics (cobas, molecular diagnostics competing with Cepheid), life sciences tools, and pharma — overlapping with Danaher's Diagnostics and Life Sciences platforms as part of a larger, more diversified portfolio.
• Abbott Laboratories: Broad incumbent in clinical diagnostics (competing with Beckman Coulter, Radiometer, Cepheid, Alinity), patient monitoring (competing with Masimo), and medical devices — overlaps with Danaher's Diagnostics segment as part of a much broader portfolio.
• Siemens Healthineers: Broad incumbent in clinical diagnostics, laboratory equipment (competing with Beckman Coulter), and patient monitoring — overlaps with Danaher's Diagnostics platform as part of a broader healthcare technology portfolio.

Emerging players

• PerkinElmer: Comparable peer in life sciences analytics, diagnostics, and lab services, with overlapping offerings in chromatography and analytical reagents — narrower scope than Danaher but directly comparable in select Life Sciences niches.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@danahercorporation
• Facebookfacebook.com/251564811530390
• LinkedInlinkedin.com/company/danaher
• Instagraminstagram.com/danahercorporation
• Xx.com/danaher_u

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Subsidiaries19 records

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A59 records

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Danaher